Jay H. Ryu

2 months ago | jrheum.org | Caitrin M. Coffey |Cassondra A. Hulshizer |Cynthia S. Crowson |Jay H. Ryu

Epidemiology of Antisynthetase Syndrome and Risk of Malignancy in a Population-Based Cohort (1998-2019) Caitrin M. Coffey, Cassondra A. Hulshizer, Cynthia S. Crowson, Jay H. Ryu, Floranne C. Ernste The Journal of Rheumatology Jan 2025, jrheum.2024-0945; DOI: 10.3899/jrheum.2024-0945

Jan 9, 2025 | jrheum.org | Caitrin M. Coffey |Cassondra A. Hulshizer |Cynthia S. Crowson |Jay H. Ryu

Epidemiology of Antisynthetase Syndrome and Risk of Malignancy in a Population-based Cohort (1998-2019) Caitrin M. Coffey, Cassondra A. Hulshizer, Cynthia S. Crowson, Jay H. Ryu, Floranne C. Ernste The Journal of Rheumatology Jan 2025, jrheum.2024-0945; DOI: 10.3899/jrheum.2024-0945

Oct 22, 2024 | mdpi.com | Teng Moua |Misbah Baqir |Jay H. Ryu

Idiopathic pulmonary fibrosis (IPF) is a progressive and often fatal disease characterized by the accumulation of fibrotic tissue in the lung [1]. While two antifibrotic medications (nintedanib and pirfenidone) [2,3] have been shown to slow disease progression and are currently in use, a significant need remains for more effective agents that may prevent loss of lung function and even reverse fibrosis.